Tianjin Ringpu Bio-TechnologyLtd Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Tianjin Ringpu Bio-TechnologyLtd kazanç ve gelirin sırasıyla yıllık 18.3% ve 15.9% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 17.9% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 10.9% olacağı tahmin edilmektedir.

Anahtar bilgiler

18.3%

Kazanç büyüme oranı

17.9%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	18.9%
Gelir büyüme oranı	15.9%
Gelecekteki özkaynak getirisi	10.9%
Analist kapsamı	Good
Son güncelleme	22 Nov 2024

Gelecekteki son büyüme güncellemeleri

Tianjin Ringpu Bio-Technology Co.,Ltd. Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

Aug 26

Recent updates

Is There An Opportunity With Tianjin Ringpu Bio-Technology Co.,Ltd.'s (SZSE:300119) 42% Undervaluation?

Nov 25

Solid Earnings May Not Tell The Whole Story For Tianjin Ringpu Bio-TechnologyLtd (SZSE:300119)

Nov 05

These 4 Measures Indicate That Tianjin Ringpu Bio-TechnologyLtd (SZSE:300119) Is Using Debt Reasonably Well

Oct 30

The Market Lifts Tianjin Ringpu Bio-Technology Co.,Ltd. (SZSE:300119) Shares 36% But It Can Do More

Oct 08

Tianjin Ringpu Bio-Technology Co.,Ltd. Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

Aug 26

Improved Earnings Required Before Tianjin Ringpu Bio-Technology Co.,Ltd. (SZSE:300119) Shares Find Their Feet

Aug 23

Tianjin Ringpu Bio-TechnologyLtd (SZSE:300119) Seems To Use Debt Quite Sensibly

Jun 26

Impressive Earnings May Not Tell The Whole Story For Tianjin Ringpu Bio-TechnologyLtd (SZSE:300119)

Apr 05

Tianjin Ringpu Bio-Technology Co.,Ltd.'s (SZSE:300119) Subdued P/E Might Signal An Opportunity

Mar 28

Kazanç ve Gelir Büyüme Tahminleri

SZSE:300119 - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (CNY Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	3,464	618	535	634	7
12/31/2025	3,076	542	167	559	8
12/31/2024	2,614	423	107	456	8
9/30/2024	2,409	424	326	537	N/A
6/30/2024	2,354	434	186	437	N/A
3/31/2024	2,339	460	196	438	N/A
12/31/2023	2,249	453	134	378	N/A
9/30/2023	2,195	387	129	386	N/A
6/30/2023	2,170	385	156	462	N/A
3/31/2023	2,136	355	139	473	N/A
1/1/2023	2,084	347	17	389	N/A
9/30/2022	1,985	354	-1	367	N/A
6/30/2022	1,875	349	0	317	N/A
3/31/2022	1,838	369	-41	287	N/A
1/1/2022	2,007	413	77	383	N/A
9/30/2021	2,038	438	72	358	N/A
6/30/2021	2,117	454	87	408	N/A
3/31/2021	2,106	441	134	438	N/A
12/31/2020	2,000	398	129	388	N/A
9/30/2020	1,895	302	175	460	N/A
6/30/2020	1,737	255	183	417	N/A
3/31/2020	1,613	224	190	396	N/A
12/31/2019	1,467	194	154	384	N/A
9/30/2019	1,346	158	83	264	N/A
6/30/2019	1,260	137	56	216	N/A
3/31/2019	1,203	124	32	167	N/A
12/31/2018	1,190	119	62	175	N/A
9/30/2018	1,179	108	40	155	N/A
6/30/2018	1,157	117	N/A	159	N/A
3/31/2018	1,112	112	N/A	113	N/A
12/31/2017	1,047	105	N/A	110	N/A
9/30/2017	1,008	136	N/A	152	N/A
6/30/2017	993	138	N/A	155	N/A
3/31/2017	988	140	N/A	185	N/A
12/31/2016	970	133	N/A	208	N/A
9/30/2016	943	129	N/A	214	N/A
6/30/2016	905	113	N/A	221	N/A
3/31/2016	832	108	N/A	223	N/A
12/31/2015	793	110	N/A	225	N/A
9/30/2015	690	68	N/A	172	N/A
6/30/2015	639	43	N/A	131	N/A
3/31/2015	625	34	N/A	140	N/A
12/31/2014	585	27	N/A	130	N/A
9/30/2014	669	95	N/A	138	N/A
6/30/2014	676	113	N/A	136	N/A
3/31/2014	722	140	N/A	116	N/A
12/31/2013	755	152	N/A	89	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: 300119 'nin tahmini kazanç büyümesi (yıllık 18.3% ) tasarruf oranının ( 2.8% ) üzerindedir.

Kazançlar ve Piyasa: 300119 şirketinin kazançlarının (yıllık 18.3% ) CN pazarından (yıllık 26.3% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: 300119 şirketinin kazançlarının artması bekleniyor, ancak önemli ölçüde.

Gelir ve Pazar: 300119 şirketinin gelirinin (yıllık 15.9% ) CN pazarından (yıllık 13.9% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: 300119 şirketinin gelirinin (yıllık 15.9% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: 300119 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 10.9 %).

Tianjin Ringpu Bio-TechnologyLtd Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Consensus EPS estimates fall by 12%

Price target decreased by 8.2% to CN¥17.97

Tianjin Ringpu Bio-Technology Co.,Ltd. Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

Price target decreased by 7.4% to CN¥19.56

Price target decreased by 7.9% to CN¥21.74

Price target decreased by 9.0% to CN¥23.21

Recent updates

New major risk - Shareholder dilution

Now 24% overvalued after recent price rise

Is There An Opportunity With Tianjin Ringpu Bio-Technology Co.,Ltd.'s (SZSE:300119) 42% Undervaluation?

Consensus EPS estimates fall by 12%

Tianjin Ringpu Bio-Technology Co.,Ltd. (SZSE:300119) announces an Equity Buyback for CNY 160 million worth of its shares.

Investor sentiment improves as stock rises 19%

Solid Earnings May Not Tell The Whole Story For Tianjin Ringpu Bio-TechnologyLtd (SZSE:300119)

Third quarter 2024 earnings released: EPS: CN¥0.19 (vs CN¥0.21 in 3Q 2023)

These 4 Measures Indicate That Tianjin Ringpu Bio-TechnologyLtd (SZSE:300119) Is Using Debt Reasonably Well

Investor sentiment deteriorates as stock falls 16%

The Market Lifts Tianjin Ringpu Bio-Technology Co.,Ltd. (SZSE:300119) Shares 36% But It Can Do More

Tianjin Ringpu Bio-Technology Co.,Ltd. to Report Q3, 2024 Results on Oct 24, 2024

Investor sentiment improves as stock rises 18%

Price target decreased by 8.2% to CN¥17.97

Tianjin Ringpu Bio-Technology Co.,Ltd. Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

Second quarter 2024 earnings released: EPS: CN¥0.15 (vs CN¥0.21 in 2Q 2023)

Improved Earnings Required Before Tianjin Ringpu Bio-Technology Co.,Ltd. (SZSE:300119) Shares Find Their Feet

Price target decreased by 7.4% to CN¥19.56

Now 20% overvalued

Tianjin Ringpu Bio-Technology Co.,Ltd. to Report First Half, 2024 Results on Aug 24, 2024

Tianjin Ringpu Bio-TechnologyLtd (SZSE:300119) Seems To Use Debt Quite Sensibly

First quarter 2024 earnings released: EPS: CN¥0.19 (vs CN¥0.17 in 1Q 2023)

Impressive Earnings May Not Tell The Whole Story For Tianjin Ringpu Bio-TechnologyLtd (SZSE:300119)

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Tianjin Ringpu Bio-Technology Co.,Ltd., Annual General Meeting, Apr 19, 2024

Tianjin Ringpu Bio-Technology Co.,Ltd.'s (SZSE:300119) Subdued P/E Might Signal An Opportunity

Now 23% overvalued

Investor sentiment improves as stock rises 16%

Now 33% overvalued

Price target decreased by 7.9% to CN¥21.74

Tianjin Ringpu Bio-Technology Co.,Ltd. to Report Fiscal Year 2023 Results on Mar 30, 2024

Tianjin Ringpu Bio-Technology Co.,Ltd. (SZSE:300119) announces an Equity Buyback for CNY 80 million worth of its shares.

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Tianjin Ringpu Bio-Technology Co.,Ltd. to Report Q3, 2023 Results on Oct 26, 2023

Price target decreased by 9.0% to CN¥23.21

Second quarter 2023 earnings released: EPS: CN¥0.21 (vs CN¥0.15 in 2Q 2022)

Tianjin Ringpu Bio-Technology Co.,Ltd. Announces 2022 Final Profit Distribution Plan to Be Implemented (A Shares), Payment Date: 08 June 2023

First quarter 2023 earnings released: EPS: CN¥0.17 (vs CN¥0.16 in 1Q 2022)

Price target increased by 8.2% to CN¥26.04

Consensus EPS estimates fall by 10%, revenue upgraded

High number of new and inexperienced directors

Third quarter 2022 earnings released: EPS: CN¥0.20 (vs CN¥0.22 in 3Q 2021)

Tianjin Ringpu Bio-Technology Co.,Ltd. Announces Executive Appointments

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.15 (vs CN¥0.22 in 2Q 2021)

Tianjin Ringpu Bio-Technology Co.,Ltd. Announces Cash Dividend of A Shares for 2021, Payable on 13 June 2022

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to CN¥25.13

No independent directors

Tianjin Ringpu Bio-Technology Co.,Ltd. Approves Cash Dividend for the Year 2021

Consensus EPS estimates fall by 24%

Tianjin Ringpu Bio-Technology Co.,Ltd., Annual General Meeting, Apr 18, 2022

Tianjin Ringpu Bio-Technology Co.,Ltd., Annual General Meeting, Apr 18, 2022

Price target decreased to CN¥25.13

Tianjin Ringpu Bio-Technology Co.,Ltd. Proposes Dividend for Year 2021

Full year 2021 earnings: EPS and revenues miss analyst expectations

Third quarter 2021 earnings released: EPS CN¥0.22 (vs CN¥0.26 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.22 (vs CN¥0.19 in 2Q 2020)

Investor sentiment deteriorated over the past week

First quarter 2021 earnings released: EPS CN¥0.29 (vs CN¥0.18 in 1Q 2020)

Investor sentiment improved over the past week

Tianjin Ringpu Bio-Technology Co., Ltd. Proposes Cash Dividend for the Year 2020

Tianjin Ringpu Bio-Technology Co., Ltd. announced that it expects to receive CNY 1.336 billion in funding

Earnings beat expectations, revenue disappoints

Full year 2020 earnings released: EPS CN¥1.01 (vs CN¥0.49 in FY 2019)

New 90-day high: CN¥26.39

Investor sentiment improved over the past week

New 90-day high: CN¥23.90

Tianjin Ringpu Bio-Technology Co., Ltd. to Report Fiscal Year 2020 Results on Mar 16, 2021